Form 4: Agenus CEO Garo Armen Opts for Stock-Based Salary, Increasing Stake in Company

Agenus Inc. CEO and Director Garo H. Armen has acquired 3,480 shares of common stock as part of his salary payment, increasing his direct and indirect beneficial ownership in the company.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 3,480 shares of Agenus common stock on June 13, 2025.
• The shares were acquired at a price of $4.70 per share, which was the closing price of Agenus Common Stock on the transaction date.
• This acquisition represents the net amount of Dr. Armen's salary for the pay period ending June 13, 2025, paid in stock instead of cash at his request and with the approval of the Agenus Inc. Compensation Committee.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested upon issuance.
• Following this transaction, Dr. Armen directly owns 194,009 shares of Common Stock.
• Additionally, Dr. Armen indirectly owns 31,298 shares held in his IRA accounts and 28,950 shares through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, bringing his total beneficial ownership to 254,257 shares.

Sentiment

Score: 7

Explanation: The decision by the CEO to take salary in stock rather than cash is generally viewed positively by the market as it signals confidence in the company's future and aligns management's interests with shareholders.

Positives

• The CEO, Garo H. Armen, elected to receive his salary in company stock instead of cash, which can be interpreted as a strong vote of confidence in the company's future performance and alignment with shareholder interests.
• The shares acquired are fully vested upon issuance, indicating immediate ownership and commitment.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Garo H. Armen requested and received approval from the Agenus Inc. Compensation Committee to have his salary paid in stock, in lieu of cash, for the pay period ending June 13, 2025.

Industry Context

This transaction is a routine insider filing (Form 4) common across all industries, including biotechnology. It reflects a compensation decision by a key executive to receive equity rather than cash, a practice often seen as a sign of confidence in the company's long-term prospects and alignment with shareholder interests, particularly in growth-oriented sectors like biotech where equity incentives are prevalent.

Related Party Transactions

• The transaction involves the payment of salary in stock to Garo H. Armen, the Chairman and CEO, which constitutes a related party transaction between the company and its executive.

Stakeholder Impact

• Shareholders may view the CEO's decision to accept stock in lieu of cash as a positive signal, indicating management's belief in the company's long-term value and commitment to aligning with shareholder interests.

Key Dates

Keywords

Agenus, AGEN, Garo H. Armen, CEO, Director, Insider Trading, Stock Acquisition, Equity Compensation, SEC Form 4, Biotechnology, Pharmaceuticals